Originally posted by chuckChuck
View Post
According to PHE, the effectiveness of both the Oxford/AstraZeneca and BioNTech/Pfizer vaccines in preventing symptomatic disease after a single dose drops to 33 per cent because of the Delta variant.
But, after two doses, this figure rises steeply to 60 per cent for Oxford/AstraZeneca and 88 per cent for BioNTech/Pfizer.
But, after two doses, this figure rises steeply to 60 per cent for Oxford/AstraZeneca and 88 per cent for BioNTech/Pfizer.
Comment